Management of Metastatic Castration-Resistant Prostate Cancer After First-Line Docetaxel
Management of mCRPC After First-Line Docetaxel
JA Harrington, RJ Jones
Yes
20110510
2011 Jun 10
Eur J Cancer
Management of Metastatic Castration-Resistant Prostate Cancer After First-Line Docetaxel
Eur J Cancer. 2011 Jun 10;[Epub Ahead of Print], JA Harrington, RJ Jones
Abstract
Abstract
Although chemotherapy, based on docetaxel, is now established in the management of metastatic castration-resistant prostate cancer (mCRPC), until recently, there has been no treatment licensed for use in the second line in men whose disease progresses during or after docetaxel therapy. This article reviews the classes of agents that have shown potential in this setting, notably chemotherapy drugs, hormonal therapies, immunotherapies, anti-angiogenic drugs, and clusterin-targeted therapy.
